At Spectramed®, our mission is to lead the way in the advancement of medical and rehabilitation tools to restore function to the highest level possible to improve the quality of life for all patients. We believe clinicians and patients alike should have access to the most comprehensive therapy suite in a global market.
Guardian Dysphagia Therapy® is a program designed to train speech-language pathologists in a protocol which utilizes fundamental electrophysiological principles that have been used successfully for over thirty years in neurorehabilitation. Our students learn to apply these principles to the treatment of dysphagia across the lifespan. Guardian® Therapy was developed by expert speech-language pathologists, and it represents a fundamentally different approach to the treatment of dysphagia.
Meet The Course Instructor
Dr. David T. Hutchings, Chief Operations Officer
Dr. David Hutchings specializes in geriatric neuropathology and Dementia. He practices as the Chief Operations Officer for Spectramed overseeing the company’s operational performance and clinical quality. Previously he practiced as the Chief Executive Officer for Stonerise Therapy. Dr. Hutchings is also the founder of Dementia and Alzheimer’s Care, LLC a private practice firm focused on the evaluation, treatment and clinical education of all forms of dementia.
In 2018, Dr. Hutchings completed a two-year fellowship with the Aspen Institute which is focused on improving health care globally through policy and practice. The Health Innovators Fellows are an elite group comprised of the top medical practitioners internationally who work to improve healthcare and healthcare delivery.
Relevant Financial Relationships:
- David Hutchings receives compensation as a course instructor.
Relevant Nonfinancial Relationships:
- Member of ASHA